End-use Segment Analysis: Oncology (Largest Segment) vs Neurology (Fastest-Growing Segment)

The oncology segment dominated the nuclear imaging devices market with a 51.94% share in 2026. Nuclear imaging technologies are extensively utilized in cancer detection, staging, treatment planning, and therapy monitoring due to their ability to provide detailed functional information about tumors. The growing emphasis on early diagnosis and precision medicine has strengthened the role of nuclear imaging in oncology workflows. Additionally, the increasing use of advanced imaging techniques for evaluating treatment response continues to support the segment’s leading position.

Neurology is the fastest-growing end-use segment, driven by rising interest in the diagnosis and management of neurological disorders. Nuclear imaging plays an important role in assessing brain function, identifying neurodegenerative conditions, and supporting research into complex neurological diseases. Growing awareness of brain health, combined with advances in imaging technologies that enable earlier and more accurate diagnosis, is accelerating adoption within neurological applications.

End User Segment Analysis: Hospitals (Largest Segment) vs Diagnostic Imaging Centers (Fastest-Growing Segment)

Hospitals held the largest share of the market in 2026. Their leadership is supported by comprehensive healthcare infrastructure, access to specialized medical professionals, and the availability of advanced imaging equipment required for nuclear medicine procedures. Hospitals often manage a broad range of complex cases requiring integrated diagnostic and treatment services, making them the primary setting for nuclear imaging utilization. Continued investments in diagnostic capabilities further reinforce their dominant market position.

Diagnostic imaging centers are emerging as the fastest-growing end-user segment due to their ability to provide specialized imaging services with greater accessibility and operational efficiency. These facilities often offer focused expertise, shorter waiting times, and dedicated diagnostic workflows, making them increasingly attractive to both patients and referring physicians. Rising demand for outpatient diagnostic services is contributing significantly to segment growth.

Product Type Segment Analysis: Single Photon Emission Computed Tomography (SPECT) (Largest Segment) vs Positron Emission Tomography (PET) (Fastest-Growing Segment)

Single photon emission computed tomography (SPECT) accounted for the largest share of the nuclear imaging devices market in 2026. The technology is widely utilized across cardiology, oncology, and neurology applications due to its established clinical utility, broad availability, and cost-effective diagnostic capabilities. SPECT systems support functional imaging across a variety of disease areas, making them an integral component of nuclear medicine departments worldwide.

Positron emission tomography (PET) is the fastest-growing product type segment, supported by its superior sensitivity and ability to provide detailed metabolic and molecular information. PET imaging is increasingly adopted for advanced disease characterization, treatment monitoring, and precision medicine applications. Ongoing advancements in radiotracer development and the growing demand for highly accurate diagnostic imaging are further accelerating the expansion of the PET segment.